Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 14 h ago

ADARx Pharmaceuticals, Inc.: Li Zhen amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Li Zhen filed an amended Schedule 13G with the SEC (accession 0001729510-26-000012) updating their beneficial ownership stake in ADARx Pharmaceuticals, Inc. The filing signals a change in Li Zhen's position in the company, though the article does not specify the exact share count or percentage held. Schedule 13G amendments are typically filed by passive investors when their ownership crosses or adjusts past the 5% threshold. Investors should watch for the updated ownership figures in the filing to gauge whether Li Zhen increased or reduced their stake.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

ADARx Pharmaceuticals, Inc., Li Zhen